about
Targeting the erythropoietin receptor on glioma cells reduces tumour growthIDH1(R132H) mutation increases U87 glioma cell sensitivity to radiation therapy in hypoxia.Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastropheDetection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.Multimodal imaging based on MRI and PET reveals [(18)F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma.Noninvasive assessment of hypoxia with 3-[18F]-fluoro-1-(2-nitro-1-imidazolyl)-2-propanol ([18F]-FMISO): a PET study in two experimental models of human glioma.M2 macrophages are more resistant than M1 macrophages following radiation therapy in the context of glioblastoma.Longitudinal Study of Irradiation-Induced Brain Microstructural Alterations With S-Index, a Diffusion MRI Biomarker, and MR Spectroscopy.VCAM-1 targeted alpha-particle therapy for early brain metastasesIn vivo surface dosimetry with a scintillating fiber dosimeter in preclinical image-guided radiotherapyTSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human gliomaPromoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Members Reveals Specific Alteration Pattern in Diffuse Gliomas64Cu-ATSM/64Cu-Cl2 and their relationship to hypoxia in glioblastoma: a preclinical studyHadrontherapy Interactions in Molecular and Cellular BiologySRC Tyrosine Kinase Inhibitor and X-rays Combined Effect on Glioblastoma Cell Lines
P50
Q28584214-BFEEF83A-2FA8-495E-9626-A3E14AD0C49EQ33660428-959AFB67-48E9-4841-A27A-533AC158676EQ35273402-EDE55646-B2B5-4432-B0FC-F0191BAD84A6Q36500372-C64E6D1B-1387-4490-B16D-BB2A0925C1C6Q38822001-B831D88C-660F-4C88-A40C-C47DFDDC6909Q39469151-1F4C070A-4F6D-41D1-9140-3AEC2C9909B3Q42700764-B8BF8DF3-C60D-4D32-A225-AD42ED844D46Q52572521-7DF16CDB-525D-4631-9CFC-C0A6419D83D0Q90184977-930C565C-57CA-4D3F-AADB-02C16A4C5CD4Q91121385-309D101B-7424-48A2-BE7D-C61D61AE0F7EQ91355510-6CF80FFD-31F9-4A71-A2E9-5F3B64D198AEQ91760290-886D1C48-C94C-426C-8318-BD5962F660CCQ92136818-52936120-145A-4567-98C9-E64FF3E21D52Q92258563-8E5C4F8B-42A6-40BC-B0A5-6B2DA7C03128Q96116536-CEF29865-179F-4849-B42C-5C0A29CDF333
P50
description
researcher ORCID ID = 0000-0002-6687-1939
@en
wetenschapper
@nl
name
Elodie A Pérès
@ast
Elodie A Pérès
@en
Elodie A Pérès
@nl
type
label
Elodie A Pérès
@ast
Elodie A Pérès
@en
Elodie A Pérès
@nl
prefLabel
Elodie A Pérès
@ast
Elodie A Pérès
@en
Elodie A Pérès
@nl
P106
P108
P31
P496
0000-0002-6687-1939